279 related articles for article (PubMed ID: 35464416)
1. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
Front Immunol; 2022; 13():828560. PubMed ID: 35464416
[TBL] [Abstract][Full Text] [Related]
2. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
3. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
Front Immunol; 2022; 13():813072. PubMed ID: 35250988
[TBL] [Abstract][Full Text] [Related]
4. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
[TBL] [Abstract][Full Text] [Related]
5. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
[TBL] [Abstract][Full Text] [Related]
9. A deep-learning model using enhanced chest CT images to predict PD-L1 expression in non-small-cell lung cancer patients.
Liu PM; Feng B; Shi JF; Feng HJ; Hu ZJ; Chen YH; Zhang JP
Clin Radiol; 2023 Oct; 78(10):e689-e697. PubMed ID: 37460338
[TBL] [Abstract][Full Text] [Related]
10. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
11. Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer.
Li B; Su J; Liu K; Hu C
Eur J Radiol Open; 2024 Jun; 12():100549. PubMed ID: 38304572
[TBL] [Abstract][Full Text] [Related]
12. Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.
Ligero M; Serna G; El Nahhas OSM; Sansano I; Mauchanski S; Viaplana C; Calderaro J; Toledo RA; Dienstmann R; Vanguri RS; Sauter JL; Sanchez-Vega F; Shah SP; Ramón Y Cajal S; Garralda E; Nuciforo P; Perez-Lopez R; Kather JN
Cancer Res Commun; 2024 Jan; 4(1):92-102. PubMed ID: 38126740
[TBL] [Abstract][Full Text] [Related]
13. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
[TBL] [Abstract][Full Text] [Related]
14. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
[TBL] [Abstract][Full Text] [Related]
15. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
[TBL] [Abstract][Full Text] [Related]
16. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade.
Peng J; Zhang J; Zou D; Xiao L; Ma H; Zhang X; Li Y; Han L; Xie B
Front Immunol; 2022; 13():960459. PubMed ID: 36420269
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study.
Xie W; Jiang Z; Zhou X; Zhang X; Zhang M; Liu R; Zheng L; Xin F; Lu Y; Wang D
Acad Radiol; 2023 Jul; 30(7):1317-1328. PubMed ID: 36369191
[TBL] [Abstract][Full Text] [Related]
19. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
Lim CH; Koh YW; Hyun SH; Lee SJ
Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
[TBL] [Abstract][Full Text] [Related]
20. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Saad MB; Hong L; Aminu M; Vokes NI; Chen P; Salehjahromi M; Qin K; Sujit SJ; Lu X; Young E; Al-Tashi Q; Qureshi R; Wu CC; Carter BW; Lin SH; Lee PP; Gandhi S; Chang JY; Li R; Gensheimer MF; Wakelee HA; Neal JW; Lee HS; Cheng C; Velcheti V; Lou Y; Petranovic M; Rinsurongkawong W; Le X; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Antonoff MB; Sepesi B; Lewis J; Wistuba II; Hazle JD; Chung C; Jaffray D; Gibbons DL; Vaporciyan A; Lee JJ; Heymach JV; Zhang J; Wu J
Lancet Digit Health; 2023 Jul; 5(7):e404-e420. PubMed ID: 37268451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]